Cleveland Clinic and IBM Research published a peer-reviewed framework (Q-CHIPP) in Science Advances that uses quantum convolutional neural networks, executed on an IBM System One QPU installed at Cleveland Clinic, to predict which tumor neoantigens will trigger a therapeutic immune response.

This is a real clinical dataset, a real named hospital partner running IBM hardware on-site, and a statistically significant result in a peer-reviewed journal, a genuinely higher bar than most "quantum for healthcare" press releases. It's also a concrete example of the kind of near-term utility Krishna's 2028-29 revenue claim (covered earlier this week) depends on actually materializing.

A real result on real patient data is worth taking seriously, and Cleveland Clinic's own IBM System One deployment (not a cloud rental) shows a genuine on-premise health system customer relationship. Still worth noting: this is a research collaboration published in an academic journal, not a commercial product IBM is selling, no revenue or licensing structure is attached to this specific result.

"Quantum Convolutional HLA Immunogenic Peptide Prediction (Q-CHIPP): Next-Generation Neoantigen Prediction with Quantum Neural Networks," Science Advances, July 24, 2026, https://www.science.org/doi/10.1126/sciadv.aec3824.